Sector News

Novozymes announces leadership changes

December 21, 2017
Chemical Value Chain

Novozymes announces the appointment of Ms. Prisca Havranek-Kosicek as new Chief Financial Officer effective February 1, 2018.

Ms. Havranek-Kosicek has up until November 2017 served as CFO and member of the Executive Board for Kuoni Group, a leading 8,000-employee service provider to the global travel industry. In the period 2011-2016 Ms. Havranek-Kosicek held positions at Royal DSM, including Group Treasurer and CFO for DSM’s pharmaceutical division, and from 2004-2008 she served as VP Corporate Subsidiaries and Investor Relations for Austrian Airlines Group.

CEO Peder Holk Nielsen says: “With a strong business acumen from international positions around the world, a thorough understanding of the different finance functions and knowledge of Novozymes’ markets, Prisca brings the right competencies and drive to support our future growth. I’m very pleased to see her become part of our Executive Leadership Team.”

Ms. Prisca Havranek-Kosicek says: “I’m honored to join Novozymes, the global leader in biological solutions with a strong cultural heritage and values. What sets Novozymes apart is the company’s innovation track record and its commitment to help solve some of the pressing global challenges facing the world today. I look forward to working with the great people at Novozymes to continue this journey.”

Ms. Havranek-Kosicek (1975) is an Austrian citizen. She currently lives in Zurich, Switzerland, and will relocate to Denmark during 2018 with her family. She has previously worked in Austria, Germany, the Netherlands, Malaysia and the US.

Ms. Havranek-Kosicek holds a Ph.D. in Business Administration from the Vienna University of Economics and Business. She serves as member of the Supervisory Board of Allianz Elementar Versicherungs-AG and Allianz Elementar Lebensversicherungs-AG.

Ms. Havranek-Kosicek will take part in the 2017-2019 Executive Leadership Team’s incentive program on a proportional basis from February 1, 2018. A description of this program, introduced on January 18, 2017, can be found in the “Group financial statement for 2016. Company announcement No. 1.”

Source: Novozymes

comments closed

Related News

December 3, 2022

Corteva to acquire Stoller Group for $1.2 billion

Chemical Value Chain

Corteva (Indianapolis, Indiana) says it has signed a definitive agreement to acquire Stoller Group (Houston, Texas), a producer of biostimulants and plant nutrition products, for $1.2 billion. Stoller is one of the largest independent biologicals companies globally, with operations in more than 60 countries and more than $400 million in annual sales.

December 3, 2022

OMV introduces new corporate structure to drive sustainable growth and innovation

Chemical Value Chain

OMV has announced its new corporate structure today, designed to fully enable the delivery of Strategy 2030. The new organization will be built on five distinct areas. In addition to the CEO and CFO areas, three business segments will be established: Chemicals & Materials, Fuels & Feedstock, and Energy.

December 3, 2022

What does the current downturn in industrial manufacturing mean for executives searching for a senior role in the chemicals industry?

Chemical Value Chain

The European petchem sector is readying for some tough quarters. It’s a different picture in the US. So is this the best time ever to find a new role in the chemical industry? If you are in Europe, you would expect me to say probably not. But actually, it depends. So let me give you four answers to this question.